DURECT Corporation (DRRX)
USD 0.73
(-2.8%)
USD 0.73
(-2.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.68 Million USD | -11.54% |
| 2022 | -32.78 Million USD | 3.47% |
| 2021 | -33.98 Million USD | -182.01% |
| 2020 | -11.8 Million USD | 33.08% |
| 2019 | -18.57 Million USD | 20.54% |
| 2018 | -22.49 Million USD | -1691.26% |
| 2017 | -833 Thousand USD | 96.06% |
| 2016 | -31.81 Million USD | -57.74% |
| 2015 | -20 Million USD | 2.54% |
| 2014 | -20.35 Million USD | 0.96% |
| 2013 | -20.6 Million USD | -223.24% |
| 2012 | 17.16 Million USD | 191.08% |
| 2011 | -17.58 Million USD | 20.9% |
| 2010 | -20.64 Million USD | 24.38% |
| 2009 | -27.74 Million USD | 31.12% |
| 2008 | -45.76 Million USD | -112.79% |
| 2007 | -22.22 Million USD | 19.41% |
| 2006 | -28.97 Million USD | -121.35% |
| 2005 | -12.45 Million USD | 38.71% |
| 2004 | -18.43 Million USD | -18.96% |
| 2003 | -16.53 Million USD | 52.28% |
| 2002 | -34.65 Million USD | -92.03% |
| 2001 | -32.07 Million USD | 15.38% |
| 2000 | -21.32 Million USD | -135.67% |
| 1999 | -9.04 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.66 Million USD | -757.16% |
| 2024 Q2 | -3.4 Million USD | 53.91% |
| 2023 Q2 | -9.54 Million USD | 9.19% |
| 2023 Q1 | -10.5 Million USD | -7.03% |
| 2023 Q3 | -8.9 Million USD | 6.67% |
| 2023 Q4 | -6.37 Million USD | 28.38% |
| 2023 FY | - USD | -11.54% |
| 2022 Q2 | -10.92 Million USD | -6.29% |
| 2022 FY | - USD | 3.47% |
| 2022 Q3 | -1.84 Million USD | 83.08% |
| 2022 Q4 | -9.81 Million USD | -431.11% |
| 2022 Q1 | -10.27 Million USD | -58.95% |
| 2021 Q2 | -8.61 Million USD | 10.03% |
| 2021 Q4 | -6.46 Million USD | 31.39% |
| 2021 Q1 | -9.57 Million USD | -15.88% |
| 2021 FY | - USD | -182.01% |
| 2021 Q3 | -9.42 Million USD | -9.35% |
| 2020 Q3 | -8.78 Million USD | -159.01% |
| 2020 Q4 | -8.26 Million USD | 5.92% |
| 2020 Q1 | -9.29 Million USD | -156.6% |
| 2020 FY | - USD | 33.08% |
| 2020 Q2 | 14.89 Million USD | 260.21% |
| 2019 Q1 | -6.41 Million USD | 3.53% |
| 2019 Q3 | -1.36 Million USD | 79.13% |
| 2019 Q2 | -6.52 Million USD | -1.6% |
| 2019 FY | - USD | 20.54% |
| 2019 Q4 | -3.62 Million USD | -166.13% |
| 2018 Q4 | -6.65 Million USD | -223.95% |
| 2018 FY | - USD | -1691.26% |
| 2018 Q3 | -2.05 Million USD | 67.74% |
| 2018 Q2 | -6.36 Million USD | 17.03% |
| 2018 Q1 | -7.67 Million USD | -186.64% |
| 2017 Q4 | 8.85 Million USD | 31.6% |
| 2017 FY | - USD | 96.06% |
| 2017 Q1 | -7.41 Million USD | 9.87% |
| 2017 Q2 | -9.21 Million USD | -24.19% |
| 2017 Q3 | 6.73 Million USD | 173.04% |
| 2016 Q4 | -8.23 Million USD | -1.16% |
| 2016 Q1 | -7.19 Million USD | -36.08% |
| 2016 Q2 | -8.35 Million USD | -16.1% |
| 2016 Q3 | -8.13 Million USD | 2.56% |
| 2016 FY | - USD | -57.74% |
| 2015 Q4 | -5.28 Million USD | 10.84% |
| 2015 Q3 | -5.92 Million USD | -23.42% |
| 2015 Q2 | -4.8 Million USD | -15.81% |
| 2015 Q1 | -4.14 Million USD | 22.54% |
| 2015 FY | - USD | 2.54% |
| 2014 Q3 | -6.53 Million USD | -23.5% |
| 2014 FY | - USD | 0.96% |
| 2014 Q1 | -3.44 Million USD | 32.36% |
| 2014 Q4 | -5.35 Million USD | 18.03% |
| 2014 Q2 | -5.29 Million USD | -53.6% |
| 2013 Q4 | -5.09 Million USD | 10.84% |
| 2013 Q3 | -5.71 Million USD | -11.02% |
| 2013 Q2 | -5.14 Million USD | -4.49% |
| 2013 Q1 | -4.92 Million USD | 4.69% |
| 2013 FY | - USD | -223.24% |
| 2012 FY | - USD | 191.08% |
| 2012 Q1 | 31.01 Million USD | 1536.54% |
| 2012 Q2 | -4.35 Million USD | -114.04% |
| 2012 Q3 | -4.54 Million USD | -4.5% |
| 2012 Q4 | -5.16 Million USD | -13.54% |
| 2011 Q3 | -5.01 Million USD | 0.75% |
| 2011 FY | - USD | 20.9% |
| 2011 Q4 | -2.15 Million USD | 56.94% |
| 2011 Q1 | -6.1 Million USD | -3.72% |
| 2011 Q2 | -5.05 Million USD | 17.3% |
| 2010 Q4 | -5.89 Million USD | -25.56% |
| 2010 Q2 | -6.33 Million USD | -6.26% |
| 2010 Q3 | -4.69 Million USD | 25.96% |
| 2010 Q1 | -5.96 Million USD | 27.27% |
| 2010 FY | - USD | 24.38% |
| 2009 Q2 | -6.79 Million USD | 19.15% |
| 2009 Q3 | -5.18 Million USD | 23.75% |
| 2009 Q4 | -8.19 Million USD | -58.19% |
| 2009 FY | - USD | 31.12% |
| 2009 Q1 | -8.4 Million USD | -86.91% |
| 2008 Q2 | -7.98 Million USD | -10.2% |
| 2008 Q4 | -4.49 Million USD | 49.06% |
| 2008 Q3 | -8.83 Million USD | -10.6% |
| 2008 Q1 | -7.24 Million USD | -23.87% |
| 2008 FY | - USD | -112.79% |
| 2007 Q4 | -5.84 Million USD | 17.74% |
| 2007 Q3 | -7.11 Million USD | -12827.27% |
| 2007 Q1 | -8.49 Million USD | 10.57% |
| 2007 Q2 | -55 Thousand USD | 99.35% |
| 2007 FY | - USD | 19.41% |
| 2006 FY | - USD | -121.35% |
| 2006 Q1 | -5.27 Million USD | -2.09% |
| 2006 Q2 | -3.59 Million USD | 31.82% |
| 2006 Q3 | -8.31 Million USD | -131.25% |
| 2006 Q4 | -9.49 Million USD | -14.15% |
| 2005 Q4 | -5.16 Million USD | -524.91% |
| 2005 Q2 | -2.14 Million USD | 45.11% |
| 2005 FY | - USD | 38.71% |
| 2005 Q1 | -3.91 Million USD | 23.99% |
| 2005 Q3 | -827 Thousand USD | 61.5% |
| 2004 FY | - USD | -18.96% |
| 2004 Q3 | -4.96 Million USD | 10.23% |
| 2004 Q1 | -4.02 Million USD | -15.16% |
| 2004 Q4 | -5.14 Million USD | -3.69% |
| 2004 Q2 | -5.53 Million USD | -37.42% |
| 2003 Q1 | -4.82 Million USD | 36.25% |
| 2003 FY | - USD | 52.28% |
| 2003 Q4 | -3.49 Million USD | 17.18% |
| 2003 Q3 | -4.22 Million USD | -5.68% |
| 2003 Q2 | -3.99 Million USD | 17.26% |
| 2002 Q3 | -8.2 Million USD | 12.05% |
| 2002 Q2 | -9.35 Million USD | 1.65% |
| 2002 Q1 | -9.5 Million USD | 2.87% |
| 2002 FY | - USD | -92.03% |
| 2002 Q4 | -7.57 Million USD | 7.94% |
| 2001 Q4 | -9.78 Million USD | -9.18% |
| 2001 Q3 | -8.96 Million USD | -234.55% |
| 2001 Q2 | -7.36 Million USD | 216.0% |
| 2001 Q1 | -5.74 Million USD | 7.34% |
| 2001 FY | - USD | 15.38% |
| 2000 Q3 | -5.72 Million USD | -21.83% |
| 2000 Q1 | 541 Thousand USD | 0.0% |
| 2000 FY | - USD | -135.67% |
| 2000 Q2 | -5.1 Million USD | -968.76% |
| 2000 Q4 | -6.19 Million USD | -8.26% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 108.006% |
| Embecta Corp. | 245.4 Million USD | 110.059% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 122.58% |
| Dynavax Technologies Corporation | 9.66 Million USD | 355.369% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 83.556% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 115.153% |
| PainReform Ltd. | -9.56 Million USD | -157.958% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 2188.325% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -545.432% |
| SCYNEXIS, Inc. | 73.47 Million USD | 133.593% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -949.932% |
| Cosmos Health Inc. | -17.06 Million USD | -44.674% |
| Journey Medical Corporation | 1.92 Million USD | 1384.956% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -545.432% |
| Safety Shot Inc | -12.18 Million USD | -102.574% |
| Alpha Teknova, Inc. | -25.53 Million USD | 3.348% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 84.461% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 123.728% |
| Theratechnologies Inc. | -10.31 Million USD | -139.353% |
| Harrow Health, Inc. | 9.72 Million USD | 353.872% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -445.503% |
| Biofrontera Inc. | -18.45 Million USD | -33.767% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 125.121% |
| Cronos Group Inc. | -72.14 Million USD | 65.787% |
| OptiNose, Inc. | -15.55 Million USD | -58.709% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.331% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 31.589% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 193.977% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 168.508% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -529.316% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -3372.463% |
| Radius Health, Inc. | 38.31 Million USD | 164.432% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -667.76% |
| ProPhase Labs, Inc. | -14.82 Million USD | -66.48% |
| Phibro Animal Health Corporation | 84.6 Million USD | 129.175% |
| Procaps Group S.A. | 104.02 Million USD | 123.728% |
| Alvotech | -484.86 Million USD | 94.909% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -193.822% |
| Viatris Inc. | 3.51 Billion USD | 100.702% |
| Rockwell Medical, Inc. | -4.69 Million USD | -425.863% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -2339.13% |
| SIGA Technologies, Inc. | 84.15 Million USD | 129.33% |
| Tilray Brands, Inc. | -72.84 Million USD | 66.113% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 3139.901% |
| Shineco, Inc. | -26.55 Million USD | 7.042% |
| PetIQ, Inc. | 81.48 Million USD | 130.292% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -582.326% |
| Incannex Healthcare Limited | -18.5 Million USD | -33.398% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 105.932% |
| Alimera Sciences, Inc. | 7.27 Million USD | 439.252% |
| Silver Spike Investment Corp. | 7.34 Million USD | 436.289% |
| Assertio Holdings, Inc. | -222.44 Million USD | 88.903% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -518.546% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -486.058% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -46.894% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -23.23% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 83.447% |
| Hempacco Co., Inc. | -12.77 Million USD | -93.247% |
| Talphera, Inc. | -9.84 Million USD | -150.803% |
| Alvotech | -484.86 Million USD | 94.909% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 131.85% |
| Lantheus Holdings, Inc. | 491 Million USD | 105.027% |
| Currenc Group, Inc. | -1.9 Million USD | -1198.766% |
| Kamada Ltd. | 21.53 Million USD | 214.628% |
| Indivior PLC | 66 Million USD | 137.4% |
| Evoke Pharma, Inc. | -7.29 Million USD | -238.494% |
| Flora Growth Corp. | -45.87 Million USD | 46.187% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -23.23% |
| Evolus, Inc. | -41.81 Million USD | 40.961% |
| HUTCHMED (China) Limited | 25.52 Million USD | 196.694% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 110.223% |
| Akanda Corp. | -27.73 Million USD | 11.003% |